Member Info for Laura2022

Excellent news

This is an amazing new contract

These small companies are starting to really get the attention they deserves

See FAB and PYC too

1) to counter factually the nonsense posted daily by those disruptive people (feel free to ask them why they keep doing this)

2) be great if others could offer some thoughts

No offence No offence taken

1 Good to see ithe in depth presentation. (50 minutes) , had an initial listen and a good  slide fron Peter which broken down the 36 project into various sections and that pipeline was £1mln and can be a "top up process" into this pot. He said there are 9 of these which are ready to be signed. He re iterated the information from the annual report that they are targeting their best ever revenues (£1.0mln+ ) having already secured about £300k since June 2023 and with Merck back on board in August 2023 whom accounted for 40% of previous revenues (therefore about £300-400k)

Also stated they would inform the market if these were to be beaten .

From annual report:

A) pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August

B)We provide a responsive and dedicated service. Many large companies offer services in the cancer space though do not restrict themselves to cancer nor to quantitative pharmacology. As a result, we believe, many of these companies cannot offer the same level of bespoke, responsive service that Physiomics can and does.

C)The Company continues to work in the immuno-oncology space with several of its clients, and it is anticipated that the industry focus on this treatment approach is likely to continue for some time

2.Jim also mentioned that for the 1st time since Brexit 2016 UK companies like PYC cam now apply...in fact Jim said the recent project was via this route,he said clearly with dozens of countries being able to apply it is competitive but he seems hopeful of other projects

Details about Horizon below

Horizon Europe is an EU research and innovation programme. It has a budget of €95.5 billion and runs until 2027.

The UK agreed a deal to associate to Horizon Europe on 7 September 2023.

3 Also new office was to aid remote working,

Jim says should save £30k-40k per annum and will be reviewed

4 Also interesting was that he and now Pete mention Project Optimus/FDA modelling expectations in everyclient discussion

5. AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients

From PYC website regarding PYC A.I applications

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Aber

It really is pathetic qnd sad

I think news from here or VAL or both is due very soon

Wrong on salaries too

Dear me porky

It's all in the annual report

Bless

If you took the time to research Jim Hastings taken a pay rise in 6yrs in role,as one of lowest on AIM and won't take one till PYC turns profitable ( see 2022 annual meeting)

How much did DDDD BOD take before they shafted shareholders ?

No problem Spinal T

Great finish to the day here

Worth

Checking out PYC tomorrow.tiny .£2.2mln market value and fully funded with £700k+ ànd A.I capabilities I n cancer drug development

Spinal

Here is a very brief summary of recent reports and presentations, PYC have an AI techniques for helping cut the time and cost for drug development

PYC current pipeline broken down into 36 projects at various stages , and that pipeline was £1mln and can be a "top up process" into this pot as projects develop or new ones added . He said there are 9 of these which are ready to be signed. He re iterated the information from the annual report that they are targeting their best ever revenues (£1.0mln+ ) having already secured about £300k since June 2023 and with Merck back on board in August 2023 whom accounted for 40% of previous revenues (therefore about £300-400k)

Also stated they would inform the market if these were to be beaten .

From annual report:

A) pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August

B)We provide a responsive and dedicated service. Many large companies offer services in the cancer space though do not restrict themselves to cancer nor to quantitative pharmacology. As a result, we believe, many of these companies cannot offer the same level of bespoke, responsive service that Physiomics can and does.

C)The Company continues to work in the immuno-oncology space with several of its clients, and it is anticipated that the industry focus on this treatment approach is likely to continue for some time

Spinal

It's looking good for A.I/oncology and bio techlots of great information here today from Trench and others

Amazing news over on FAB today

Fantastic to see

OBD FAB and PYC

Peter which broken down the 36 project into various sections and that pipeline was £1mln and can be a "top up process" into this pot. He said there are 9 of these which are ready to be signed. He re iterated the information from the annual report that they are targeting their best ever revenues (£1.0mln+ ) having already secured about £300k since June 2023 and with Merck back on board in August 2023 whom accounted for 40% of previous revenues (therefore about £300-400k)

Also stated they would inform the market if these were to be beaten .

From annual report:

A) pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August

B)We provide a responsive and dedicated service. Many large companies offer services in the cancer space though do not restrict themselves to cancer nor to quantitative pharmacology. As a result, we believe, many of these companies cannot offer the same level of bespoke, responsive service that Physiomics can and does.

C)The Company continues to work in the immuno-oncology space with several of its clients, and it is anticipated that the industry focus on this treatment approach is likely to continue for some time

Trench

One has to ask why some people are fixated on PYC and yet post on non of the other 100+ small AIM companies

It's patently transparent the agendas

Trench

Yet again, porky is forgetting that PYC had only 1 client just 6yrs ago and now has over 40

expansion and diversification of the Company's client base, expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services and exploration of opportunities around its personalised oncology software offering

• Successful completion of the NIHR-sponsored PARTNER study at Portsmouth Hospitals University NHS Trust

• Announcement of collaboration with Beyond Blood Diagnostics for personalised cancer treatment

• Announcement of collaboration with wholly owned ValiRx subsidiary Inaphaea Biolabs Ltd

• Podium presentation at American Association for Cancer Research (AACR) on project with client Merck KGaA

• First contract directly with Cancer Research UK (relating to the clinical development of Aleta Biotherapeutics ALETA-001)

• Follow on contracts with existing clients Merck KGaA, Numab Therapeutics, Ankyra Therapeutics and Bicycle Therapeutics

• Appointment of a second highly experienced independent Non-Executive Director, Shalabh Kumar

 

And from bbc on 1st Nov

Personalised treatment'

About 4,300 people in England are diagnosed with this type of cancer each year.

Prof Messiou hopes the technology can eventually be used around the world, with high-risk patients given specific treatment while those at low risk are spared unnecessary treatments and follow-up scans.

Dr Paul Huang, from the Institute of Cancer Research, London, said: "This kind of technology has the potential to transform the lives of people with sarcoma - enabling personalised treatment plans tailored to the specific biology of their cancer.

"It's great to see such promising findings."

 Michelle Roberts

Digital health editor

At least 20,000 cancer deaths a year could be avoided in the UK with a national commitment to invest in research and innovation, and fix the NHS, says Cancer Research UK.

Progress is being made in finding new treatments for the condition that affects 50% of people at some point.

But the charity says the UK lags behind comparable countries for survival.

It has launched a manifesto of priorities for this government and the next, ahead of a general election.

The document sets out what the charity says needs to change - and fast.

Whoever is running the country must commit to developing a 10-year cancer plan, spearheaded by a National Cancer Council accountable to the prime minister to bring government, charities, industry and scientific experts together, it says

Interesting you didn't ask the same of DDDD who effectively lied and stole ££millionns of shareholder money,òr HZM who qr going to wipe out shareholders with nothing to show apart from a nickel asset that will never see light of day,or QIM companies like BIDS VRS RRR PHC and dozens more who for 20yrs have made less than £100k revenues...why target PYC who are helping fight cancer and o target for highest revenues every

Why target a company who has one of lowest paid CEOs in small caps (many corrup CEOs have extortionate £350-300k+ salaries eg VRS LVCG PREMand dozens more. PYC CEO has achieved more revenues in the last 6yrs than the whole combined 17 years before him, has had no pay rise above his modest £130k salary at all and stated he will not have one until PYC is self sustaining ( VLS directors earn £1mln between 2 directors!)

They target a company that is growing revenues since the CEO took over and diversification of clients and have stated the are aiming for RECORD EVER revenues

A company that is seen as invaluable to over 60 clients many of whom on NASDAQ such as Bicycle

Chosen by Cancer Research UK to partner its UK work programmes

Aiming to fight Cancer (particularly)

Were on course for £900k+ revenues but 3 clients in Q1 2023 had a paused /be late(NOT cancelled ) on their work for PYC ( explained In Fridays Q and A)

People who spend time trying to rubbish the company clearly have a strange moral compass

Https://www.bbc.co.uk/news/health-67486722

Looks like for the 1.30pm trade unless someone knows what they are?